Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 19, 2007 Brian Lawler	Abbott on Top Abbott announces second-quarter financial results. Shares of Abbott aren't particularly expensive, considering the growth potential for its top compounds and its strong drug pipeline with compounds in development for several blockbuster indications.
BusinessWeek January 29, 2007 Michael Arndt	Abbot Labs: Diagnosis: Shrewd Moves Abbott Laboratories has announced that it is selling about two-thirds of its $4 billion diagnostics business to buy more medical products outfits to help boost overall sales and profits by at least 10% a year into the next decade.
The Motley Fool December 18, 2008 Brian Orelli	A Diagnostic Tongue Twister Back-scratch fever between Abbott and Isis.
The Motley Fool June 4, 2010 Jim Mueller	The Changing Face of Abbott Abbott Labs' shift in revenue sources has been a boon over the last five years.
The Motley Fool January 30, 2007 Brian Lawler	Is Bigger Better for Abbott Labs? Abbott continues its transformation into a more focused pharmaceutical powerhouse. But shares of this pharmaceutical aren't exactly cheap.
The Motley Fool October 18, 2006 Brian Lawler	Is a Buyback the Best Abbott Can Do? Abbott Labs may be out of ideas for its cash. Investors, take note.
The Motley Fool January 22, 2007 Jack Uldrich	GE's Plastic Surgery The shift away from the plastics business toward diagnostics is risky. Bottom line: The conglomerate could be paying a lot for something that isn't really needed, and it would be better off just trying to take better care of its existing business.
The Motley Fool December 30, 2008 Brian Orelli	A Post-Holiday Breakup ... of Sorts Abbott and Celera revise their partnership.
The Motley Fool November 13, 2006 Brian Lawler	Kos' Swan Song The drug company releases what will probably be its last earnings announcement before a buyout by Abbot Labs. Investors, take note.
The Motley Fool July 13, 2005 Stephen D. Simpson	Is Abbott's Ailment Serious? There's room for improvement at Abbott Labs, but this is one solid and broadly diversified company. Shares aren't a screaming bargain, but the current price-to-earnings ratio really isn't out of line with history.
The Motley Fool November 15, 2011 Dan Caplinger	Has Abbott Labs Become the Perfect Stock? For long-term investors, Abbott's continuing devotion to up its dividend -- its streak now stands at 39 years -- makes a compelling reason to hold onto your shares.
The Motley Fool July 19, 2006 Stephen D. Simpson	No Vow of Poverty for This Abbott Abbott Labs delivers a solid quarter with broad-based growth. Investors, the stock is moderately undervalued and likely to be a worthwhile long-term holding.
The Motley Fool January 18, 2005 Stephen D. Simpson	Abbott Still Looks Healthy Never a too-big roaring growth stock or a too-small low-growth behemoth, the medical products company seems just right as it dependably keeps on performing for investors.
The Motley Fool April 19, 2006 Stephen D. Simpson	Abbott Gets By Will the acquisition of Guidant's vascular business kick-start this story? Abbott has shown a pretty reliable trend of getting cheap enough to buy at least once a year. Of course, the downside to that is that the stock really hasn't gone anywhere in those seven years.
The Motley Fool October 15, 2008 Brian Orelli	Abbott's Stents Aren't (That) Important Abbott's shareholders shouldn't be too focused on drug-eluting stents.
The Motley Fool April 22, 2010 Brian Orelli	Abbott's Stuck in a Double-Digit Rut The company keeps cranking out solid earnings, but investors don't seem to care.
The Motley Fool January 25, 2006 Stephen D. Simpson	Abbott Wins No matter what Boston Scientific does with Guidant, Abbott looks like a winner. This stock might not offer a rocket ride the way smaller biotechs and med-tech companies do, but at today's prices, at least you won't have to worry about a fiery re-entry.
The Motley Fool July 29, 2010 Brian Orelli	Is Abbott a Buy? Whether or not Abbott is a buy depends on management's ability to transition the company.
BusinessWeek September 22, 2003	This Baby May Outdo Its Parent Some orphans are better off without their parents -- corporately speaking, that is. My hunch is this may apply to shares due to spring forth next year from health-care giant Abbott Laboratories.
The Motley Fool January 19, 2007 Anders Bylund	GE Bulks Up: Fool by Numbers The conglomerate released fourth-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Management Effectiveness... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool April 20, 2007 Billy Fisher	Feverish Growth at Meridian Bioscience Looking to add a small-cap health-care stock to your portfolio? You might want to carefully consider the recent performance and future prospects of diagnostic-test-kit maker Meridian Bioscience.
The Motley Fool October 24, 2011 Sean Williams	There's More to GE's Earnings Than Meets the Eye Wall Street didn't like the earnings report, but one analyst sure did.
The Motley Fool January 23, 2007 Billy Fisher	Strong Start at Meridian Bioscience From an earnings standpoint, the Cincinnati-based life science company reported another record quarter, and it should continue to impress onlookers in the months ahead.
The Motley Fool June 29, 2010 Brian Orelli	Redeploying Capital? Investors Hope So. Selling a business unit won't help Abbott Labs diversify.
The Motley Fool September 28, 2009 Rick Aristotle Munarriz	Abbott Labs Looks Less Lopsided Abbott Labs' $6.6 billion purchase of Solvay's pharmaceuticals business is just what the doctor ordered.
The Motley Fool August 22, 2008 Brian Orelli	Abbott Tries a Crash Diet The health-care conglomerate is cutting jobs in its diagnostic testing division.
The Motley Fool January 17, 2007 Anders Bylund	Foolish Forecast: Go, GE, Go The conglomerate is set to report earnings for the fourth quarter and full fiscal year 2006 shortly. Let's see what investors should expect out this complex giant.
The Motley Fool November 14, 2011 Dan Caplinger	Has General Electric Become the Perfect Stock? For GE to continue its march toward perfection, it needs to keep getting back to its industrial roots.
The Motley Fool September 5, 2008 Brian Orelli	Zimmer Fortifies Its Spine The medical-device maker is buying Abbott's spine business.
The Motley Fool October 25, 2010 Rich Smith	GE: $5 Billion Down, $25 Billion to Go GE spends, but not wisely.
The Motley Fool October 12, 2004 Brian Gorman	Abbott's Healthy Diet Is the company's push into nutritional supplements a wise move?
The Motley Fool April 12, 2004 Brian Gorman	Abbott Not Rewarded Abbott Laboratories first-quarter earnings news was positive, but investors didn't react enthusiastically.
The Motley Fool October 19, 2005 Stephen D. Simpson	Abbott Still a Little Pale Perhaps drug and device pipelines, plus margin improvements, can put some color back into the diversified health-care company's stock.
The Motley Fool July 17, 2008 Brian Orelli	Investors Yawn at Abbott Labs' Growth Abbott Labs may be firing on all cylinders, but investors were less than impressed with its earnings release
The Motley Fool April 13, 2004 Lita Epstein	GE Bets on Health Care Closing a $9.5 billion deal for the U.K.'s Amersham assures a major role for GE Healthcare.
The Motley Fool April 8, 2005 Stephen D. Simpson	Abbott Hopes to Maxx Out Abbott announced FDA approval to begin a pivotal trial for its drug-eluting stent. Will this be too little too late for shareholders, or a true dark horse?
The Motley Fool August 6, 2007 Billy Fisher	IDEXX Checks Out in Good Health Earnings continue to surge for this veterinary diagnostics manufacturer. Investors, take note.
The Motley Fool February 23, 2004 Brian Gorman	Abbott Cleans Up Its Act Abbott closes the books on its problems with the FDA and clears the way to a spinoff. Abbott finally passed FDA muster with its Illinois diagnostics plant. Its multi-year problem highlights the importance of investors monitoring manufacturing while watching a pharmaceutical company's pipeline. And with its FDA compliance issues behind it, Abbott can look forward to spinning off its Hospital Products Division.
The Motley Fool January 22, 2009 Brian Orelli	Abbott Labs Thumbs Nose at Recession On a GAAP basis, Abbott Labs fourth-quarter earnings per share were up a whopping 27%, and even better, the double-digit increases don't look like they're going to stop anytime soon.
The Motley Fool October 20, 2011 Brian Orelli	Mini J&J? I Guess Not Abbott says it plans to split in two: drugs in one company, everything else in the other.
The Motley Fool July 14, 2009 Brian Orelli	Diagnosing a Personalized Partnership Abbott and Glaxo hook up on diagnostics.
Chemistry World October 21, 2011 Sarah Houlton	Abbott Splits to Set Pharma Portfolio Free Abbott Laboratories is to be split in two and claims the aim is to strengthen the outlook for growth and shareholder returns.
The Motley Fool November 8, 2011 Brian Wilson	2 Health-Care Stocks for Times of Uncertainty Just because Abbott and Johnson & Johnson don't undertake as much risk as other health-care giants doesn't mean that shareholders won't see impressive growth in revenues.
The Motley Fool May 11, 2010 Brian Orelli	Abbott Makes a Push Into Selling Leftovers Abbott Labs has jumped on the established-product-division bandwagon. The company has licensed 24 products from Zydus Cadila of India and has the option to market another 40.
The Motley Fool January 19, 2011 Brian Orelli	A Painfully Protracted Partner Depomed is in a bind.
Pharmaceutical Executive July 1, 2009 Stan Bernard	Forget Brand vs. Brand--This is War Increasingly, pharma companies are expanding from brand vs. brand to battle at the franchise, portfolio, and corporate levels.
The Motley Fool February 24, 2009 Brian Orelli	Pfizer: Diversified Dreams, Dubious Decisions Pfizer's CEO Jeffrey Kindler said he wants to make his company more like Johnson & Johnson and Abbott Labs, which aren't dependent on one product for success.
The Motley Fool October 27, 2010 Ralph Casale	Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment.
The Motley Fool January 27, 2011 Brian Orelli	Abbott Labs: Growth in All the Wrong Places Abbott's a solid company with solid dividend and growth potential in the near term. But investors need to be careful extrapolating that growth out.
BusinessWeek April 14, 2011 Rachel Layne	GE and Siemens: Less May Mean More (Profits) The medical gear makers see an opportunity for their information technology units as hospitals are pressured to improve efficiency and curb waste